Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2. fázis

Corticosteroids in Hyperinflammatory Phenotype of Critical Illness

A legfontosabb adatok

Ki végzi
Bin Du
Hol
Kína11 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
150 fő, tervezett
Kezdés
2026. ápr. 15.
Várható befejezés
2028. jún. 1.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Methylprednisolone (MP)
  • Placebo
A regiszteradat frissítve
2026. november 18.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 17 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥ 18 years
  • Onset of ARDS and/or sepsis within 72 hours; ARDS is defined according to the Berlin definition: onset within 1 week of a known clinical insult or new or worsening respiratory symptoms; bilateral opacities on chest imaging not fully explained by pleural effusions, lobar or lung collapse, or nodules; respiratory failure not fully explained by cardiac failure or fluid overload; and PaO2/FiO2 ≤300 mmHg with PEEP ≥ 5 cm H2O; Sepsis is defined according to Sepsis-3 as suspected or confirmed infection accompanied by an acute increase in SOFA score of ≥ 2 points attributable to infection
  • Requirement for invasive mechanical ventilation
  • Hyperinflammatory phenotype, defined as a predicted probability ≥ 0.50 using the clinical classifier
  • Written informed consent provided by the participant or a legally authorised representative

Ki nem vehet részt

  • Systemic corticosteroid exposure at a prednisone-equivalent dose > 0.3 mg/kg/day within the 3 weeks preceding randomisation, or use of any immunosuppressive agent within the same period.[16]
  • Solid-organ transplantation or allogeneic stem-cell transplantation
  • Concurrent participation in another interventional clinical trial
  • Severe congenital or acquired immunodeficiency, including HIV infection
  • Brain death, expected death within 24 hours, or advanced malignancy or other end-stage disease with a life expectancy of less than 6 months
  • Life-threatening active fungal infection or active tuberculosis
  • Known hypersensitivity to corticosteroids
  • Neuromuscular disease that substantially impairs spontaneous breathing
  • Any other clinical condition that, in the opinion of the treating physician or investigator, makes participation inappropriate
  • High vasopressor requirement, defined as a norepinephrine-equivalent dose (NEE) ≥ 0.25 μg/kg/min
  • A do-not-resuscitate order or a decision to withdraw or withhold life-sustaining treatment
  • Pregnancy or lactation

Ez a vizsgálat jelenleg itt érhető el: Kína.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to learn whether methylprednisolone improves outcomes in critically ill patients with a hyperinflammatory phenotype. It will also evaluate the safety of methylprednisolone at different doses.

A teljes eredeti leírásKevesebb

The main questions it aims to answer are:

* Does methylprednisolone improve organ function compared with placebo? * Does methylprednisolone reduce the risk of mortality within 30 days?

Researchers will compare high-dose methylprednisolone (160mg/d), low-dose methylprednisolone (80mg/d), and placebo (normal saline) to evaluate effectiveness and safety.

Participants will:

* Receive high-dose methylprednisolone, low-dose methylprednisolone, or placebo every 12 hours for the first 3 days * Be reassessed on Day 4 based on their inflammatory status If the hyperinflammatory phenotype persists, the treatment dose will be reduced by half and continued until Day 7 or ICU discharge, whichever occurs first If the patient transitions to a hypoinflammatory phenotype, the study treatment will be discontinued * Be monitored daily in the intensive care unit for organ function, inflammatory status, and need for organ support * Be followed for up to 30 days after randomization to assess survival and recovery

A vizsgálat 3 csoportja

  • high dose methylprednisolone groupA vizsgált kezelés

    Methylprednisolone 80 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 40 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.

    Kezelés: Methylprednisolone (MP)

  • low dose methylprednisolone groupA vizsgált kezelés

    Methylprednisolone 40 mg intravenously every 12 hours for the first 3 days. On day 4, prior to administration, patients will be reassessed; if the hyperinflammatory phenotype persists, the dose will be reduced to 20 mg every 12 hours and continued until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.

    Kezelés: Methylprednisolone (MP)

  • placebo groupPlacebo, összehasonlításként

    Normal saline (100 mL) will be administered intravenously every 12 hours for the first 3 days. On day 4, patients will be reassessed prior to dosing; if the hyperinflammatory phenotype persists, normal saline (100 mL) will continue to be administered every 12 hours until day 7 or ICU discharge, whichever occurs first. Treatment will be discontinued if patients transition to a hypoinflammatory phenotype on day 4.

    Kezelés: Placebo

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Efficacy, Safety, and Tolerability of Methylprednisolone in Critically Ill Patients With the Hyperinflammatory Phenotype: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Trial
A regiszteradat frissítve
2026. november 18.